What you’re overlooking is that the overhang to MNTA’s share price from Teva’s Lovenox program is now essentially gone.
If by some chance Teva actually got FDA approval, MNTA’s lawsuit against Teva (which has already been filed) would likely play out in a manner similar to MNTA’s lawsuit against Amphastar.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”